Page 67 - Micro5 Brochure 2017

waveforms and durations of 15 and 189 h, respectively. Treatment was applied over 3 weeks.
Assessments were at baseline and 3, 6 and 15 weeks.

RESULTS:
For each trial, n = 31. In trial 1, 50 μA was more effective than 500 μA, with 93% of participants 'much
better' or 'fully recovered' at 15 weeks, compared with 47% in the 500 μA group. Tendon structural
normalization was superior at 50 μA, but no significant differences were found in other outcomes. In trial
2, success rates for the two groups at 15 weeks were 75% and 73%, respectively, but group
improvements did not differ significantly on any measure. Pooled analysis of data from both trials showed
that, immediately following treatment, blood flow had fallen in the subgroup with high baseline scores and
risen in the subgroup with low scores. Low baseline score correlated significantly with treatment success.

CONCLUSION:
Monophasic MCT of peak current intensity 50 μA applied for tens of hours may be effective in reducing
symptoms and promoting tendon normalization in chronic tennis elbow. Hyperaemia may help predict
treatment outcome. A full-scale trial of the therapy is warranted.

Copyright © 2011 John Wiley & Sons, Ltd.

Rehabilitation (Stuttg). 2010 Jun;49(3):173-9. doi: 10.1055/s-0029-1246152. Epub 2010 Jun 8.

[Effectiveness of microcurrent therapy as a constituent of post-
hospital rehabilitative treatment in patients after total knee
alloarthroplasty - a randomized clinical trial].

[Article in German]
Rockstroh G1, Schleicher W, Krummenauer F.
Author information
Abstract
PURPOSE:
This trial compared the clinical effectiveness of a combination of microcurrent therapy (M) with
conventional postoperative physiotherapy treatment versus the combination of the latter with a sham (S)
treatment after total knee arthroplasty (TKA) in terms of patient-related functional outcome parameters.

METHODS:
A total of 78 inpatients after TKA was randomized into the active versus the sham treatment samples; all
patients received ten applications of their respective therapy assignment. The primary clinical endpoint of
the investigation was defined as the three-months intraindividual change (%) in a patient's OSWESTRY
total function score after start of treatment. Secondary endpoints were the WOMAC osteoarthritis index as
well as a patient's pain profile as assessed by a visual analogue scale before start of treatment, after five
and ten therapeutic applications, and three months after discharge from hospital.

RESULTS:
The M sample showed a median increase of 31% (22-38%) in the OSWESTRY total score from 53%
before start of treatment to 91% three months afterwards; the control sample showed an increase of 18%
(3-31%) in median from 56 % to 78%; the samples differed significantly in this three-months increase
(p<0,001) but not in the baseline OSWESTRY score before start of treatment (p=0,841).

CONCLUSION: